The Lancet publishes first clinical trial data of a fully bioabsorbable drug-elu...( ABBOTT PARK Ill. March 13 2008 Data...),Health
ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007. Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.
"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."
At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the overall MACE rate in the ABSORB trial was consistent with results at 6 months (one patient, 3.3 percent, n=30; 3.4 percent adjusted for one patient who withdrew from follow-up, known to be event free at 1 year, n=29). MACE is a composite measure of cardiac death, hear
'/>"/>
| Contact: Karin Bauer 408-845-3887 Abbott Laboratories Source:Eurekalert |
Related medicine news :
1. Two studies published in the Lancet
2. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
3. MediPurpose Sells 500 Millionth Safety Lancet to IMCO Member MMS Medical
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. American College of Physicians publishes The Fenway Guide to LGBT Health
6. In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish
7. Multiple Sclerosis Association of America Publishes Booklet about Depression in Multiple Sclerosis
8. American College of Physicians publishes "Peripheral Arterial Disease"
9. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |